Life science business consultants
4D Biomedical is a specialist adviser on:
-
Healthcare markets
-
Technology development
-
Business strategy
-
Venture financing
Formed by a management team which has worked together over the last fifteen years establishing some of the UK’s most successful bio-ventures, 4D Biomedical is an advisory business set up to help support two key client groups:
- Companies with real innovation in the fast evolving biomedical sector where emerging technology and new healthcare markets converge.
- Investors
- Specialist life science investors interested in the new and emerging biomedical space.
- New, overseas and small cap investors coming into the UK biomedical market.
- Other organisations with a significant exposure to the market such as property companies, venture finance providers and banks.
UK life science venturing
UK life science venturing has been transformed in the last two years. The rise of AIM, VCTs, new regional and specialist funds and angels is driving new financing models. Pharma, clinical and regulatory reforms are driving new markets. Continued scientific progress into the biological mechanisms of human health and disease is unlocking new diagnostic, device and therapeutic opportunities.
The challenge for investors and companies alike is to adapt to this new market.
We work with some of the most innovative investors, companies and healthcare bodies shaping this new market in the UK. We provide consultancy services both on a traditional project basis and through long term strategic relationships with clients.
Our team of nine executives is headquartered in Cambridge, UK. Contact us to find out what we can do for your business.
UK Bio-venturing - What's going on?
Lessons from the last 6 months deal flow.
George Freeman, 4D Biomedical, presented at the Biotechnology Investment Forum at Babraham on 3rd October 2007.
Translational Medicine Research Collaboration is awarded “Best Investment in Europe”
Wyeth Pharmaceuticals has been awarded one of three 'Best Investment in Europe' titles at the La Baule World Investment Conference for its role in creating the world's first Translational Medicine Research Collaboration (TMRC) in Scotland in 2006.
The 4D Biomedical team advised Scottish Enterprise on the collaboration.
UK Bio-venturing: lessons from the last six months of deals
The presentation given by 4D Biomedical at the Biotechnology Investment Forum at Babraham on 3rd May 2007.
UK life science 2006: lessons from recent deals
4D Biomedical presented to a plenary session at the Biotechnology Investment Forum at Babraham on 4th October 2006.
Translational medicine
The 4D Biomedical team advised on the ground breaking $50m biomarker collaboration between the NHS, four UK universities and Wyeth Pharmaceuticals announced in April 2006.